Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorAluja Gonzalez, David
dc.contributor.authorDelgado Tomás, Sara
dc.contributor.authorRuiz Meana, Marisol
dc.contributor.authorBarrabés Riu, José Antonio
dc.contributor.authorInserte Igual, Javier
dc.date.accessioned2022-09-07T11:18:10Z
dc.date.available2022-09-07T11:18:10Z
dc.date.issued2022-04
dc.identifier.citationAluja D, Delgado-Tomás S, Ruiz-Meana M, Barrabés JA, Inserte J. Calpains as Potential Therapeutic Targets for Myocardial Hypertrophy. Int J Mol Sci. 2022 Apr;23(8):4103.
dc.identifier.issn1422-0067
dc.identifier.urihttp://hdl.handle.net/11351/8042
dc.descriptionCalpain; Calpastatin; Myocardial hypertrophy
dc.description.abstractDespite advances in its treatment, heart failure remains a major cause of morbidity and mortality, evidencing an urgent need for novel mechanism-based targets and strategies. Myocardial hypertrophy, caused by a wide variety of chronic stress stimuli, represents an independent risk factor for the development of heart failure, and its prevention constitutes a clinical objective. Recent studies performed in preclinical animal models support the contribution of the Ca2+-dependent cysteine proteases calpains in regulating the hypertrophic process and highlight the feasibility of their long-term inhibition as a pharmacological strategy. In this review, we discuss the existing evidence implicating calpains in the development of cardiac hypertrophy, as well as the latest advances in unraveling the underlying mechanisms. Finally, we provide an updated overview of calpain inhibitors that have been explored in preclinical models of cardiac hypertrophy and the progress made in developing new compounds that may serve for testing the efficacy of calpain inhibition in the treatment of pathological cardiac hypertrophy.
dc.language.isoeng
dc.publisherMDPI
dc.relation.ispartofseriesInternational Journal of Molecular Sciences;23(8)
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceScientia
dc.subjectInsuficiència renal aguda - Tractament
dc.subjectEnzims - Ús terapèutic
dc.subject.meshHeart Failure
dc.subject.mesh/drug therapy
dc.subject.meshCalpain
dc.titleCalpains as Potential Therapeutic Targets for Myocardial Hypertrophy
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.3390/ijms23084103
dc.subject.decsinsuficiencia cardíaca
dc.subject.decs/farmacoterapia
dc.subject.decscalpaína
dc.relation.publishversionhttps://doi.org/10.3390/ijms23084103
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Aluja D, Delgado-Tomás S] Grup de Recerca en Malalties Cardiovasculars, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Ruiz-Meana M, Barrabés JA, Inserte J] Grup de Recerca en Malalties Cardiovasculars, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Centro de Investigación en Red de Enfermedades Cardiovasculares (CIBERCV), 28029 Madrid, Spain
dc.identifier.pmid35456920
dc.identifier.wos000785143600001
dc.relation.projectidinfo:eu-repo/grantAgreement/ES/PE2017-2020/PI20%2F01681
dc.relation.projectidinfo:eu-repo/grantAgreement/ES/PE2013-2016/CB16%2F11&2F00479
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record